Quantum BioPharma is trading at $2.47, up +10.40%, with no clear company-specific explanation identified for the October 23 after-hours rise. - On October 22, reports noted FDA clearance for Lucid-MS Phase 2 testing and a Rodman & Renshaw Buy rating with an $8 price target; neither establishes a direct cause. - Major indices were mixed, so broad-market direction does not clearly explain the gain.